Skip to Main Content

++

INTRODUCTION

++

esomeprazole (es-oh-mep-ra-zole)

Nexium

Classification

Therapeutic: antiulcer agents

Pharmacologic: proton-pump inhibitors

++
Indications
++

GERD/erosive esophagitis. Hypersecretory conditions, including Zollinger-Ellison syndrome. With amoxicillin and clarithromycin to eradicate Helicobacter pylori in duodenal ulcer disease or history of duodenal ulcer disease. Decrease risk of gastric ulcer during continuous NSAID therapy.

++
Action
++

Binds to an enzyme on gastric parietal cells in the presence of acidic gastric pH, preventing the final transport of hydrogen ions into the gastric lumen. Therapeutic Effects: Diminished accumulation of acid in the gastric lumen with lessened gastroesophageal reflux. Healing of duodenal ulcers. Decreased incidence of gastric ulcer during continuous NSAID therapy.

++
Adverse Reactions/Side Effects
++

CNS: headache. GI: abdominal pain, constipation, diarrhea, dry mouth, flatulence, nausea.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor improvements in GI symptoms (gastritis, heartburn, and so forth) to help determine if drug therapy is successful.

++
Interventions
++

  • In cases of NSAID-induced gastritis, implement appropriate manual therapy techniques, physical agents, and therapeutic exercises to reduce pain and decrease the need for aspirin and other NSAIDs.

++
Patient/Client-Related Instruction
++

  • Advise patient to avoid alcohol and foods that may cause an increase in GI irritation.

  • Instruct patient to report bothersome or prolonged side effects, including headache or GI effects (nausea, constipation, diarrhea flatulence, abdominal pain, dry mouth).

++
Pharmacokinetics
++

Absorption: 90% absorbed following oral administration; food decreases absorption.

++

Distribution: Unknown.

++

Protein Binding: 97%.

++

Metabolism and Excretion: Extensively metabolized by the liver (cytochrome P450 [CY P450] system, primarily CYP2C19 isoenzyme); <1% excreted unchanged in urine.

++

Half-life: 1.0–1.5 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (blood levels*)

ROUTE ONSET PEAK DURATION
PO rapid 1.6 hr 24 hr
IV rapid end of infusion 24 hr

*Resolution of symptoms takes 5–8 days.

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity; OB: Lactation (not recommended).

++

Use Cautiously in: Severe hepatic impairment (daily dose should not exceed 20 mg); Geri: Increased risk of hip fractures in patients using high doses for >1 year; OB: Pregnancy (use only if clearly needed); Pedi: Children <1 yr (safety not established).

++
Interactions
++

Drug-Drug: May ↓ absorption of drugs requiring acid pH, including ketoconazole, itraconazole, atazanavir, ampicillin, iron salts, and digoxin. May ↑ risk of bleeding with warfarin (monitor INR and PT).

++
Route/Dosage
++
Gastroesophageal Reflux Disease
++

PO (Adults): Healing of erosive esophagitis—20 or 40 mg once daily for 4–8 wk; maintenance of healing of erosive esophagitis—20 mg once daily; symptomatic GERD—20 mg once daily for 4 wk (additional 4 ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.